Entera Bio Ltd.

NasdaqCM ENTX

Entera Bio Ltd. Price to Earnings Ratio (P/E) on December 30, 2024: -8.75

Entera Bio Ltd. Price to Earnings Ratio (P/E) is -8.75 on December 30, 2024, a -45.20% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Entera Bio Ltd. 52-week high Price to Earnings Ratio (P/E) is -5.93 on February 07, 2024, which is 32.18% above the current Price to Earnings Ratio (P/E).
Entera Bio Ltd. 52-week low Price to Earnings Ratio (P/E) is -13.82 on March 21, 2024, which is -57.95% below the current Price to Earnings Ratio (P/E).
Entera Bio Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -8.43.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: ENTX

Entera Bio Ltd.

CEO	Ms. Miranda J. Toledano M.B.A.
IPO Date	June 28, 2018
Location	Israel
Headquarters	Kiryat Hadassah Minrav Building
Employees	17
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Key trends

Past 5 years